Simvastatin as Add-On Treatment to Escitalopram in Patients With Major Depression and Obesity
Authors:
Open Access
- 1 August 2025
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Psychiatry
- Vol. 82 (8) , 759
Abstract
Importance: Major depressive disorder (MDD) and obesity are common noncommunicable disorders associated with substantial disease burden, which frequently occur comorbidly. Intriguingly, converging lines of evidence from animal models and genetic and observational studies have suggested a biological link between obesity, metabolic syndrome, and depression. Several small randomized clinical trials (RCTs) have suggested the antidepressive potential of statins.Objective: To examine whether simvastatin added to escitalopram is efficacious in improving depressive symptoms compared with add-on placebo.Design, Setting, and Participants: This was a confirmatory, double-blind, placebo-controlled, multicenter RCT. Adults with MDD and comorbid obesity from 9 tertiary care settings in Germany were enrolled in this analysis. Data were analyzed from July to October 2024.Interventions: Simvastatin (40 mg per day) or placebo as add-on to escitalopram (10 mg for the first 2 weeks, then increased to 20 mg until the end of study) in a double-blind fashion for 12 weeks.Main Outcomes and Measures: The primary outcome was change in Montgomery-Åsberg Depression Rating Scale (MADRS) score from baseline (week 0) to week 12.Results: From August 21, 2020, to June 06, 2024, a total of 161 patients were enrolled at 9 sites in Germany, of which 160 patients were included in the intention-to-treat analysis (placebo: n = 79, simvastatin: n = 81; mean [SD] age, 39.0 [11.0] years; 126 female [79%]). Retention in the trial was excellent (95.6%), and blinding was effectively maintained. There were 4 serious adverse events with no difference between the groups. Primary end point analysis in the intention-to-treat sample showed no significant treatment effect of add-on simvastatin in MADRS scores (mixed models for repeated measures least squares mean difference, 0.47 points; 95% CI, −2.08 to 3.02; P = .71). No effects of simvastatin treatment were observed in any of the mental health–related secondary end points. However, simvastatin treatment significantly reduced low-density lipoprotein cholesterol (simvastatin, −40.37 mg/dL; 95% CI, −47.41 to −33.33 mg/dL; placebo, −3.78 mg/dL; 95% CI, −11.18 to 3.62 mg/dL; P < .001), total cholesterol (simvastatin, −39.07 mg/dL; 95% CI, −49.42 to −28.73 mg/dL; placebo, −4.89 mg/dL; 95% CI, −15.64 to 5.87 mg/dL; P < .001), and C-reactive protein (simvastatin, −1.04 mg/L; 95% CI, −1.89 to −0.20 mg/L; placebo, 0.57 mg/L; 95% CI, −0.28 to 1.42 mg/L; P = .003) compared with placebo.Conclusions and Relevance: The study failed to meet its primary end point. This demonstrates that simvastatin did not exert additional antidepressive effects when added to escitalopram in patients with comorbid MDD and obesity, despite improving the cardiovascular risk profile.Trial Registration: ClinicalTrials.gov Identifier: NCT04301271Keywords
This publication has 34 references indexed in Scilit:
- Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: A double-blind placebo-controlled trialJournal of Psychopharmacology, 2015
- In a randomized, double-blind clinical trial, adjuvant atorvastatin improved symptoms of depression and blood lipid values in patients suffering from severe major depressive disorderJournal of Psychiatric Research, 2014
- Statins use and risk of depression: A systematic review and meta-analysisJournal of Affective Disorders, 2014
- AUGMENTATION OF FLUOXETINE WITH LOVASTATIN FOR TREATING MAJOR DEPRESSIVE DISORDER, A RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED-CLINICAL TRIALDepression and Anxiety, 2013
- Influence of trial sample size on treatment effect estimates: meta-epidemiological studyBMJ, 2013
- Differences in the prescribing of medication for physical disorders in individuals withv.without mental illness: meta-analysisThe British Journal of Psychiatry, 2012
- Overweight, Obesity, and DepressionArchives of General Psychiatry, 2010
- Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning.2000
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979
- An Inventory for Measuring DepressionArchives of General Psychiatry, 1961